Consistency Evaluation TOP10 Enterprises Released!

According to data from Minet.

Among the TOP10 reviewed companies, Yangzijiang Pharmaceutical Group ranked first with 105 varieties, Qilu Pharmaceutical ranked second with 98 varieties, Sino Biopharmaceutical ranked third with 85 varieties, Kelun Pharmaceuticals, CSPC Group 74 and 72 varieties have been reviewed respectively

Five companies including Better Pharmaceuticals, Fosun Pharmaceuticals, Hengrui Pharmaceuticals, Shanghai Pharmaceuticals, and Sunshine Pharmaceuticals ranked sixth to tenth

Top 10 companies with over-reviewed generic drugs (as of 2022/4/22)

The Yangtze River is up! 105 Reviewed Varieties Dominate the Screen

Yangtze River Pharmaceutical Group passed/deemed to pass the consistency evaluation varieties

The speed of the Yangtze River is amazing!

At the beginning of 2021, Yangzijiang Pharmaceutical Group ranked third in the review list

In the first quarter of 2022, Yangzijiang Pharmaceutical Group has already reviewed 11 varieties, and once again "won the championship", becoming the "one over-reviewed brother" in one fell swoop

Up to now, 105 varieties (141 product specifications) of Yangzijiang Pharmaceutical Group have passed/deemed to have passed the consistency evaluation, of which 25 varieties have passed the first evaluation, and a total of 31 varieties have won the bid for the first five batches of centralized procurement

Anti-infective drugs are the therapeutic areas that Yangzijiang Pharmaceutical Group focuses on

Also in the field of anti-infection, Yangzijiang Pharmaceutical Group has harvested its first new chemical class 1 drug

98 varieties of Qilu Pharmaceutical have been reviewed! 43 first reviews

Qilu Pharmaceutical Group passed/deemed to pass the consistency evaluation varieties

On April 14, Qilu Pharmaceutical Group announced that the 100th product, cefprozil, passed the consistency evaluation

On April 21, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's tofacitinib citrate sustained-release tablets were approved for marketing, becoming the first domestic imitation + first review

Among the 101 reviewed products, 3 varieties were reviewed by 2 subsidiaries respectively

The 98 reviewed varieties are mainly concentrated in anti-tumor and immunomodulatory agents (27), systemic anti-infective drugs (19), and nervous system drugs (16)

Imitation drives innovation, and innovation drives the future

In the past five years, Qilu Pharmaceutical Group's R&D investment has increased from 1.

85 varieties of Chinese biopharmaceuticals have been reviewed, and the generic drug business is indispensable

China Biopharmaceutical passed/deemed to pass the consistency evaluation varieties

Sino Biopharmaceutical has 85 varieties (135 specifications) that have passed/deemed to have passed the consistency evaluation, of which 32 are the first to pass the evaluation

The 85 varieties mainly focus on anti-tumor and immune modulators (21), digestive system and metabolizing drugs (15), and systemic anti-infective drugs (13)

In 2021, a total of 20 generic drugs of Sino Biopharmaceuticals have been approved for marketing, and the first class 1 biological drug Piamprimab injection (PD-1 mAb) has been obtained
.
In early 2022, the Group's first biosimilar drug, adalimumab injection, was approved for marketing, further improving the coverage of anti-tumor and immune fields
.

The performance report shows that in 2021, China's biopharmaceutical revenue will be about 26.
86 billion yuan, a record high and a year-on-year increase of 13.
6%
.
Among them, the profit attributable to the owners of the parent company was about 14.
61 billion yuan, a year-on-year increase of 427.
2%, and the adjusted net profit attributable to the parent company was 2.
93 billion yuan, a year-on-year increase of 26.
6%
.

In terms of product sales, the sales revenue in the anti-tumor field reached 9.
22 billion yuan, an increase of 21%, and the 4-year compound growth rate was 55%; the total revenue of new products launched in the five years was about 12.
1 billion yuan, and the 4-year compound growth rate was about 58%.

.

In 2021, the group's total R&D investment will reach 3.
82 billion yuan, accounting for 142.
2% of the group's revenue
.
Among them, the R&D investment of innovative drugs and biological drugs accounted for more than 70%, and the R&D investment in the anti-tumor field accounted for about 75%
.
While the innovative drugs are fully promoted, the Group believes that generic drugs are still an indispensable business for stable development
.

Epilogue

In the early stage of the Consistency Evaluation, Huahai Pharmaceuticals achieved corner overtaking by means of exporting preparations to China, and became the big winner of the first batch of centralized procurement
.
With the extension of the front line, traditional leading pharmaceutical companies have gradually become "over-evaluated" generic drugs through the "consistency evaluation supplementary application + new registration classification" two-way force, and continue to play the main force in the new round of national centralized procurement
.

When the stock varieties are gradually digested, the incremental varieties allow all enterprises to stand on the same starting line, and rich product clusters have become the key to breaking through
.
The once-famous barefoot enterprises gradually fade out, and the leading enterprises will move from the strong to the strong to the strong
.
It is still the choice of most domestic pharmaceutical companies to insist on making innovative drugs while continuing to make generic drugs
.